Skip to content
RDL Network logo
Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the <scp>VEGF‐A</scp> /caveolin‐1/ <scp>PV</scp> ‐1 signaling pathway — Monica Locatelli (2022) | RDL Network